vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and Tectonic Financial, Inc. (TECTP). Click either name above to swap in a different company.
Tectonic Financial, Inc. is the larger business by last-quarter revenue ($23.0M vs $18.7M, roughly 1.2× CytomX Therapeutics, Inc.). Tectonic Financial, Inc. runs the higher net margin — 23.8% vs -0.8%, a 24.7% gap on every dollar of revenue. On growth, Tectonic Financial, Inc. posted the faster year-over-year revenue change (17.9% vs -25.7%). CytomX Therapeutics, Inc. produced more free cash flow last quarter ($-15.8M vs $-17.3M). Over the past eight quarters, Tectonic Financial, Inc.'s revenue compounded faster (270.5% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
Tectonic Financial, Inc.TECTPEarnings & Financial Report
Tectonic Financial, Inc. is a US-based diversified financial services provider. It offers core services including wealth management, investment banking, capital markets advisory, and tailored financial solutions. Its key client segments cover high-net-worth individuals, institutional investors, and small to mid-sized enterprises across North America.
CTMX vs TECTP — Head-to-Head
Income Statement — Q2 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $23.0M |
| Net Profit | $-154.0K | $5.5M |
| Gross Margin | — | — |
| Operating Margin | -6.9% | 30.6% |
| Net Margin | -0.8% | 23.8% |
| Revenue YoY | -25.7% | 17.9% |
| Net Profit YoY | 97.6% | 15.9% |
| EPS (diluted) | — | $0.73 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | — | $23.0M | ||
| Q2 25 | $18.7M | $21.6M | ||
| Q1 25 | $50.9M | $21.8M | ||
| Q4 24 | $38.1M | $21.4M | ||
| Q3 24 | $33.4M | $19.5M | ||
| Q2 24 | $25.1M | $18.6M | ||
| Q1 24 | $41.5M | $17.6M | ||
| Q4 23 | $26.6M | $1.7M |
| Q3 25 | — | $5.5M | ||
| Q2 25 | $-154.0K | $4.3M | ||
| Q1 25 | $23.5M | $4.5M | ||
| Q4 24 | $18.9M | $3.0M | ||
| Q3 24 | $5.7M | $4.7M | ||
| Q2 24 | $-6.5M | $3.1M | ||
| Q1 24 | $13.8M | $3.1M | ||
| Q4 23 | $837.0K | $3.3M |
| Q3 25 | — | 30.6% | ||
| Q2 25 | -6.9% | 25.9% | ||
| Q1 25 | 44.4% | 26.0% | ||
| Q4 24 | 46.4% | 22.1% | ||
| Q3 24 | 12.3% | 29.1% | ||
| Q2 24 | -33.7% | 21.5% | ||
| Q1 24 | 28.1% | 22.2% | ||
| Q4 23 | -2.3% | — |
| Q3 25 | — | 23.8% | ||
| Q2 25 | -0.8% | 19.8% | ||
| Q1 25 | 46.2% | 20.4% | ||
| Q4 24 | 49.6% | 14.0% | ||
| Q3 24 | 17.2% | 24.2% | ||
| Q2 24 | -26.0% | 16.9% | ||
| Q1 24 | 33.3% | 17.4% | ||
| Q4 23 | 3.1% | 197.4% |
| Q3 25 | — | $0.73 | ||
| Q2 25 | — | $0.55 | ||
| Q1 25 | — | $0.57 | ||
| Q4 24 | — | $0.35 | ||
| Q3 24 | — | $0.58 | ||
| Q2 24 | — | $0.38 | ||
| Q1 24 | — | $0.37 | ||
| Q4 23 | — | $0.40 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $119.9M | $119.2M |
| Total Assets | $175.1M | $1.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | — | ||
| Q2 25 | $49.0M | — | ||
| Q1 25 | $47.6M | — | ||
| Q4 24 | $38.1M | — | ||
| Q3 24 | $40.6M | — | ||
| Q2 24 | $43.2M | — | ||
| Q1 24 | $36.2M | — | ||
| Q4 23 | $17.2M | — |
| Q3 25 | — | $119.2M | ||
| Q2 25 | $119.9M | $114.6M | ||
| Q1 25 | $25.0M | $111.3M | ||
| Q4 24 | $-456.0K | $113.4M | ||
| Q3 24 | $-23.5M | $112.8M | ||
| Q2 24 | $-31.2M | $110.4M | ||
| Q1 24 | $-31.7M | $108.5M | ||
| Q4 23 | $-47.4M | $106.9M |
| Q3 25 | — | $1.1B | ||
| Q2 25 | $175.1M | $997.0M | ||
| Q1 25 | $98.5M | $910.5M | ||
| Q4 24 | $120.5M | $863.4M | ||
| Q3 24 | $139.0M | $847.5M | ||
| Q2 24 | $159.2M | $777.1M | ||
| Q1 24 | $184.7M | $777.6M | ||
| Q4 23 | $201.8M | $677.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $-17.3M |
| Free Cash FlowOCF − Capex | $-15.8M | $-17.3M |
| FCF MarginFCF / Revenue | -84.6% | -74.9% |
| Capex IntensityCapex / Revenue | 0.1% | 0.0% |
| Cash ConversionOCF / Net Profit | — | -3.14× |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $-17.3M | ||
| Q2 25 | $-15.8M | $-32.5M | ||
| Q1 25 | $-21.0M | $-35.6M | ||
| Q4 24 | $-19.9M | $-86.6M | ||
| Q3 24 | $-20.7M | $-22.5M | ||
| Q2 24 | $-19.5M | $-30.7M | ||
| Q1 24 | $-26.0M | $-3.2M | ||
| Q4 23 | $-22.0M | $-16.7M |
| Q3 25 | — | $-17.3M | ||
| Q2 25 | $-15.8M | — | ||
| Q1 25 | $-21.2M | $-35.6M | ||
| Q4 24 | $-20.0M | $-86.8M | ||
| Q3 24 | $-20.7M | $-22.5M | ||
| Q2 24 | $-19.6M | $-30.7M | ||
| Q1 24 | $-26.2M | $-3.3M | ||
| Q4 23 | $-22.2M | $-16.7M |
| Q3 25 | — | -74.9% | ||
| Q2 25 | -84.6% | — | ||
| Q1 25 | -41.6% | -163.2% | ||
| Q4 24 | -52.5% | -406.5% | ||
| Q3 24 | -62.1% | -115.0% | ||
| Q2 24 | -78.2% | -165.5% | ||
| Q1 24 | -63.1% | -18.8% | ||
| Q4 23 | -83.5% | -996.2% |
| Q3 25 | — | 0.0% | ||
| Q2 25 | 0.1% | 0.0% | ||
| Q1 25 | 0.2% | 0.0% | ||
| Q4 24 | 0.2% | 1.0% | ||
| Q3 24 | 0.1% | 0.1% | ||
| Q2 24 | 0.4% | 0.3% | ||
| Q1 24 | 0.3% | 0.9% | ||
| Q4 23 | 1.0% | 0.4% |
| Q3 25 | — | -3.14× | ||
| Q2 25 | — | -7.61× | ||
| Q1 25 | -0.89× | -8.00× | ||
| Q4 24 | -1.05× | -28.99× | ||
| Q3 24 | -3.61× | -4.74× | ||
| Q2 24 | — | -9.76× | ||
| Q1 24 | -1.89× | -1.03× | ||
| Q4 23 | -26.24× | -5.04× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
TECTP
Segment breakdown not available.
